Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses  

作　　者：Lei-Ping Zeng Xing-Yi Ge Cheng Peng Wanbo Tai Shibo Jiang Lanying Du Zheng-Li Shi 

机构地区：[1]CAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences [2]Lindsley F.Kimball Research Institute, New York Blood Center [3]Key Laboratory of Medical Molecular Virology of MOE/MOH, School of Basic Medical Sciences, Fudan University

出　　处：《Science China(Life Sciences)》2017年第12期1399-1402,共4页中国科学（生命科学英文版）

基　　金：supported by the National Natural Science Foundation of China(81290341,31621061 to Zheng-Li Shi);the Strategic Priority Research Program of the Chinese Academy of Sciences(XDPB0301 to Zheng-Li Shi);National Institute of Allergy and Infectious Diseases of National Institutes of Health grant(R01AI110964 to Zheng-Li Shi);the National Key Research and Development Program of China(2016YFC1201000 to Shibo Jiang);NIH grant(R01AI098775 to Shibo Jiang and Lanying Du)

摘　　要：Dear Editor,The 2002–2003 global pandemic caused by severe acute respiratory syndrome coronavirus（SARS-CoV）infected around 8,000 people with 10%mortality（http：//www.who.int/csr/sars/en/）.Dear Editor,The 2002–2003 global pandemic caused by severe acute respiratory syndrome coronavirus(SARS-CoV)infected around 8,000 people with 10%mortality(http://www.who.int/csr/sars/en/).The virus has a positivestranded RNA genome that encodes a large polyprotein(1a and 1ab),four structural proteins,including spike(S),

关 键 词：Cross-neutralization of SARS coronavirus-specific antibodies bat SARS-like coronaviruses 

分 类 号：R392[医药卫生—免疫学]